Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02535182 · ClinicalTrials.gov registry record
Pilot Study Using Propranolol To Promote Prenylation Of Gtpase Rap1b In Hematopoietic Stem Cell Transplant Recipients
A clinical trial, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- 25
- Enrollment target
NCT02535182 is a clinical trial that has completed, run by Medical College of Wisconsin. The registered enrollment target is 25 participants.
The verdict
NCT02535182 has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
This is a an ancillary study designed to explore whether an additional cell signaling pathway (prenylation of Rap1) that was recently identified as being under beta-adrenergic control may be affected by beta-blocker use.
Interventions
- OTHER Blood Draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-08 |
| Est. Completion | 2020-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02535182
The ClinicalTrials.gov registry entry for NCT02535182 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood Draw is the first listed.
NCT02535182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02535182 about?
NCT02535182 is a clinical study titled "Pilot Study Using Propranolol To Promote Prenylation Of Gtpase Rap1b In Hematopoietic Stem Cell Transplant Recipients". This is a an ancillary study designed to explore whether an additional cell signaling pathway (prenylation of Rap1) that was recently identified as being under beta-adrenergic control may be affected by beta-blocker use.
What is the current status of trial NCT02535182?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2015-08. Estimated completion is 2020-02.
What interventions are being tested in trial NCT02535182?
The interventions under investigation include: Blood Draw (OTHER).
Who is sponsoring clinical trial NCT02535182?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.